This was in agreement with Shekarriz R et al., 2018 [12] who conducted a study on 40 patients with symptomatic MM and found that β2M value in stage III patients was significantly higher than those with stage II and stage I. The gene discussed is B2M; the disease is Miyoshi myopathy.